Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix.
Elagolix
GnRH antagonist
endometriosis
uterine fibroids
Journal
F&S reports
ISSN: 2666-3341
Titre abrégé: F S Rep
Pays: United States
ID NLM: 101766618
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
30
08
2022
revised:
30
01
2023
accepted:
01
02
2023
medline:
24
5
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
epublish
Résumé
Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval.
Identifiants
pubmed: 37223767
doi: 10.1016/j.xfre.2023.02.002
pii: S2666-3341(23)00010-7
pmc: PMC10201304
doi:
Types de publication
Journal Article
Langues
eng
Pagination
65-72Informations de copyright
© 2023 The Author.
Références
Pain Manag. 2019 Sep;9(5):497-515
pubmed: 31434540
N Engl J Med. 2020 Jan 23;382(4):328-340
pubmed: 31971678
J Med Chem. 2008 Dec 11;51(23):7478-85
pubmed: 19006286
Obstet Gynecol. 2020 Jun;135(6):1313-1326
pubmed: 32459423
Obstet Gynecol. 2018 Jul;132(1):147-160
pubmed: 29889764
Reprod Sci. 2018 Nov;25(11):1567-1576
pubmed: 30033855
J Clin Endocrinol Metab. 2017 May 1;102(5):1683-1691
pubmed: 28323948
Obstet Gynecol. 2018 Nov;132(5):1252-1264
pubmed: 30303923
Fertil Steril. 2017 Jul;108(1):152-160.e4
pubmed: 28579415
N Engl J Med. 2017 Jul 6;377(1):28-40
pubmed: 28525302
J Med Chem. 2005 Feb 24;48(4):1169-78
pubmed: 15715483
Br Med Bull. 2000;56(3):761-72
pubmed: 11255560